MOORESTOWN, N.J., March 01, 2017 -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), a healthcare technology company providing medication safety solutions for health plans and provider groups, has successfully implemented its first payer-based Care Transitions program focused on medication risk mitigation following discharge from a hospital or post-acute care facility. The purpose is to provide comprehensive medication reconciliation and optimization to prevent readmission due to medication problems.
According to TRHC Chairman and CEO, Calvin H. Knowlton, PhD, this member population is typically on multiple medications to treat chronic diseases. “Polypharmacy raises the chance of dangerous multi-drug interactions and serious side effects that can lead to hospital readmissions,” said Knowlton. “Our goal is to reduce risk for an adverse drug event by personalizing the member’s medication regimen to optimize pharmacotherapy treatment. We are excited to include our Medication Risk Mitigation Software Platform, MedWise Advisor®, as well as our personalized Medication Decision Support processes on behalf of the Plan members.”
The program, which launched January 1, 2017, provides a comprehensive medication reconciliation performed by Tabula Rasa HealthCare (TRHC) pharmacists in the health plan members’ homes within the first week following notification of discharges. Pharmacists perform a medication risk mitigation screening using the TRHC MedWise Advisor® software to determine medication risk. The TRHC pharmacists consult with the patient’s primary physician to discuss actual and potential risks with the goal of avoiding negative consequences. Members are provided information and documentation regarding their reconciled medication regimen and an action plan to discuss with their prescriber. As one member commented, “It was a learning experience; it made me feel like I had more control over my life instead of just doing what I was told. It made me feel like I had control over how I felt.”
TRHC’s proprietary science and technology Medication Risk Mitigation products and services perform 360-degree reviews and safety assessments of complex medication regimens, providing an innovative, alternative approach to personalized pharmacotherapy. The objective is to optimize medication use thereby improving outcomes, including reduction in falls, emergency room visits, and medication-related hospitalizations.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information, please visit: www.trhc.com.
Contact: Media Dianne Semingson [email protected] T: 215-870-0829 Investors Bob East or Asher Dewhurst Westwicke Partners 443-213-0500 [email protected]


TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Instagram Outage Disrupts Thousands of U.S. Users
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Washington Post Publisher Will Lewis Steps Down After Layoffs
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 



